Journament

Keyword Connections - chronic lymphocytic leukemia Keywords

Connection Type	Connection
Journals	Scientific reports Anticancer research Frontiers in oncology Leukemia research expert opinion on biological therapy Leukemia & lymphoma
Research Groups	No Research Group Connected
Bibliographies	[1] Minimal Residual Disease in Chronic Lymphocytic Leukemia: A New Goal? [2] Optimisation of robust singleplex and multiplex droplet digital PCR assays for high confidence mutation detection in circulating tumour DNA. [3] The up-to-date role of biologics for the treatment of chronic lymphocytic leukemia. [4] fludarabine induces apoptosis in chronic lymphocytic leukemia - the role of p53, bcl-2, bax, mcl-1, and bag-1 proteins [5] circulating proangiogenic cytokines and angiogenesis inhibitor endostatin in untreated patients with chronic lymphocytic leukemia [6] recurrent malignant melanoma presenting as isolated pleural metastases in a patient with chronic lymphocytic leukemia [7] bcr signaling inhibitors: an overview of toxicities associated with ibrutinib and idelalisib in patients with chronic lymphocytic leukemia [8] deregulated levels of the nf-κb1, nf-κb2, and rel genes in ukrainian patients with leukemia and lymphoma in the post-chernobyl period [9] smudge cells in peripheral blood smears did not differentiate chronic lymphocytic leukemia from other b-cell chronic lymphoprolipherative diseases sombras nucleares no esfregaço do sangue periférico não diferenciam a leucemia linfocítica crônica das outras doenças linfoproliferativas b crônicas [10] ibrutinib as a bridge to transplant in high-risk chronic lymphocytic leukemia: a case report and review of the literature [11] detection of paroxysmal nocturnal hemoglobinuria-phenotype in patients with chronic lymphocytic leukemia and multiple myeloma [12] using murine models to investigate tumor–lymphoid interactions: spotlight on chronic lymphocytic leukemia and angioimmunoblastic t-cell lymphoma [13] Overexpression of Galectin-3 in Chronic Lymphocytic Leukemia Is Associated With 17p Deletion: A Short Report. [14] Identification of new phosphorylation sites of CD23 in B-cells of patients with chronic lymphocytic leukemia. [15] Altered expression pattern of SLAM family receptors on pathological B cells of patients with chronic lymphocytic leukemia. [16] Characterization of Chronic Lymphocytic Leukemia Immunoglobulin Rearrangements from Partial Read Sequencing. [17] Automated shape-based clustering of 3D immunoglobulin protein structures in chronic lymphocytic leukemia [18] Targeting CD20 in chronic lymphocytic leukemia [19] Targeting CD20 in chronic lymphocytic leukemia [20] Targeting CD20 in chronic lymphocytic leukemia [21] Composite Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma and T-Prolymphocytic Leukemia Presenting with Lymphocytosis, Skin Lesions, and Generalized Lymphadenopathy [22] Minimal Residual Disease in Chronic Lymphocytic Leukemia: A New Goal? [23] The up-to-date role of biologics for the treatment of chronic lymphocytic leukemia. [24] Paranasal Manifestations of Early Stage Chronic Lymphocytic Leukemia [25] Immunoglobulin transcript sequence and somatic hypermutation computation from unselected RNA-seq reads in chronic lymphocytic leukemia [26] Immunoglobulin transcript sequence and somatic hypermutation computation from unselected RNA-seq reads in chronic lymphocytic leukemia [27] stim1 at the plasma membrane as a new target in progressive chronic lymphocytic leukemia [28] the spectrum of genetic defects in chronic lymphocytic leukemia [29] ofatumumab – a valid treatment option for chronic lymphocytic leukemia patients [30] spontaneous retroperitoneal hemorrhage in a patient with prolymphocytic transformation of chronic lymphocytic leukemia [31] fludarabine induces apoptosis in chronic lymphocytic leukemia - the role of p53, bcl-2, bax, mcl-1, and bag-1 proteins [32] improvement of paraneoplastic limbic encephalitis after systemic treatment with rituximab in a patient with b-cell chronic lymphocytic leukemia [33] expression of hla-g in patients with b-cell chronic lymphocytic leukemia (b-cll). [34] circulating proangiogenic cytokines and angiogenesis inhibitor endostatin in untreated patients with chronic lymphocytic leukemia [35] recurrent malignant melanoma presenting as isolated pleural metastases in a patient with chronic lymphocytic leukemia [36] aureobasidium pullulans infection in a patient with chronic lymphocytic leukemia [37] altered n-linked glycosylation in follicular lymphoma and chronic lymphocytic leukemia: involvement in pathogenesis and potential therapeutic targeting [38] fe de errores de "evaluación económica de rituximab en combinación con fludarabina y ciclofosfamida en comparación con fludarabina y ciclofosfamida en el tratamiento de la leucemia linfática crónica" erratum to "economic evaluation of rituximab added to fludarabine plus cyclophosphamide versus fludarabine plus cyclophosphamide for the treatment of chronic lymphocytic leukemia" [39] human endogenous retrovirus np9 gene is over expressed in chronic lymphocytic leukemia patients [40] peptide vaccination induces profound changes in the immune system in patients with b-cell chronic lymphocytic leukemia [41] bcr signaling inhibitors: an overview of toxicities associated with ibrutinib and idelalisib in patients with chronic lymphocytic leukemia [42] prostatic-like syndrome in a woman with chronic lymphocytic leukemia: sequential kinase inhibitor therapy [43] guidelines for diagnosis and treatment of chronic lymphocytic leukemia [44] smudge cells in peripheral blood smears did not differentiate chronic lymphocytic leukemia from other b-cell chronic lymphoprolipherative diseases sombras nucleares no esfregaço do sangue periférico não diferenciam a leucemia linfocítica crônica das outras doenças linfoproliferativas b crônicas [45] ibrutinib as a bridge to transplant in high-risk chronic lymphocytic leukemia: a case report and review of the literature [46] bcl-2 and bax interaction in b-lymphocytes of peripheral blood in patients with chronic lymphocytic leukemia [47] new developments in the treatment of chronic lymphocytic leukemia: role of obinutuzumab [48] coexistence of chronic lymphocytic leukemia and myeloproliferative neoplasm [49] detection of paroxysmal nocturnal hemoglobinuria-phenotype in patients with chronic lymphocytic leukemia and multiple myeloma [50] using murine models to investigate tumor–lymphoid interactions: spotlight on chronic lymphocytic leukemia and angioimmunoblastic t-cell lymphoma [51] Overexpression of Galectin-3 in Chronic Lymphocytic Leukemia Is Associated With 17p Deletion: A Short Report. [52] Identification of new phosphorylation sites of CD23 in B-cells of patients with chronic lymphocytic leukemia. [53] Altered expression pattern of SLAM family receptors on pathological B cells of patients with chronic lymphocytic leukemia. [54] Fludarabine combined with cyclophosphamid is highly effective in the treatment of chronic lymphocytic leukemia. [55] Characterization of a New Chronic Lymphocytic Leukemia Cell Line for Mechanistic In Vitro and In Vivo Studies Relevant to Disease [56] Pentostatin, Cyclophosphamide and Rituximab Followed by Alemtuzumab for Relapsed or Refractory Chronic Lymphocytic Leukemia: A Phase 2 Trial of the ECOG-ACRIN Cancer Research Group (E2903) [57] Characterization of a New Chronic Lymphocytic Leukemia Cell Line for Mechanistic In Vitro and In Vivo Studies Relevant to Disease [58] Frontline Therapy for Chronic Lymphocytic Leukemia: The Dilemma Continues [59] Characterization of Chronic Lymphocytic Leukemia Immunoglobulin Rearrangements from Partial Read Sequencing.